Review



gdf15 growth differentiation factor 15 levels  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems gdf15 growth differentiation factor 15 levels
    The effects of ID8 implantation on muscle mass, fat mass, spleen mass, <t>GDF15</t> and gene expression of inflammation and atrogenes. Analysis of muscle mass at all time points in hindlimb muscles was completed (A, n = 22–24; soleus (SOL), extensor digitorum longus (EDL), plantaris (PLA), tibialis anterior (TA), gastrocnemius (GA) and quadriceps (QUAD)). Subcutaneous adipose mass in the inguinal fat depot (B, n = 9–12), serum GDF15 (C, n = 8–11) and spleen mass (D, n = 21–22) were also analyzed. mRNA content of inflammatory and atrophy markers interleukin-6 (IL-6), tumour necrosis factor – alpha (TNF-α), atrogin and muscle RING-finger protein-1 (MURF-1) were measured using quantitative PCR in the TA and diaphragm of all groups (E-H, n = 6–8). Results represent mean ± SD. Lettering denotes statistical significance when different from each other ( p < 0.05). C57BL/6J female mice ∼75 days post PBS injection as controls (CTRL); C57BL/6J female mice ∼45 days post ovarian cancer injection (45 Days); C57BL/6J female mice ∼75 days post ovarian cancer injection (75 Days); C57BL/6J female mice ∼90 days post ovarian cancer injection (90 Days). All data was analyzed using a one-way ANOVA or Kruskal–Wallis test when data did not fit normality. All ANOVAs were followed by a two-stage step-up method of Benjamini, Krieger and Yukutieli multiple comparisons test.
    Gdf15 Growth Differentiation Factor 15 Levels, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 55 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gdf15 growth differentiation factor 15 levels/product/R&D Systems
    Average 94 stars, based on 55 article reviews
    gdf15 growth differentiation factor 15 levels - by Bioz Stars, 2026-03
    94/100 stars

    Images

    1) Product Images from "Muscle weakness and mitochondrial stress occur before severe metastasis in a novel mouse model of ovarian cancer cachexia"

    Article Title: Muscle weakness and mitochondrial stress occur before severe metastasis in a novel mouse model of ovarian cancer cachexia

    Journal: Molecular Metabolism

    doi: 10.1016/j.molmet.2024.101976

    The effects of ID8 implantation on muscle mass, fat mass, spleen mass, GDF15 and gene expression of inflammation and atrogenes. Analysis of muscle mass at all time points in hindlimb muscles was completed (A, n = 22–24; soleus (SOL), extensor digitorum longus (EDL), plantaris (PLA), tibialis anterior (TA), gastrocnemius (GA) and quadriceps (QUAD)). Subcutaneous adipose mass in the inguinal fat depot (B, n = 9–12), serum GDF15 (C, n = 8–11) and spleen mass (D, n = 21–22) were also analyzed. mRNA content of inflammatory and atrophy markers interleukin-6 (IL-6), tumour necrosis factor – alpha (TNF-α), atrogin and muscle RING-finger protein-1 (MURF-1) were measured using quantitative PCR in the TA and diaphragm of all groups (E-H, n = 6–8). Results represent mean ± SD. Lettering denotes statistical significance when different from each other ( p < 0.05). C57BL/6J female mice ∼75 days post PBS injection as controls (CTRL); C57BL/6J female mice ∼45 days post ovarian cancer injection (45 Days); C57BL/6J female mice ∼75 days post ovarian cancer injection (75 Days); C57BL/6J female mice ∼90 days post ovarian cancer injection (90 Days). All data was analyzed using a one-way ANOVA or Kruskal–Wallis test when data did not fit normality. All ANOVAs were followed by a two-stage step-up method of Benjamini, Krieger and Yukutieli multiple comparisons test.
    Figure Legend Snippet: The effects of ID8 implantation on muscle mass, fat mass, spleen mass, GDF15 and gene expression of inflammation and atrogenes. Analysis of muscle mass at all time points in hindlimb muscles was completed (A, n = 22–24; soleus (SOL), extensor digitorum longus (EDL), plantaris (PLA), tibialis anterior (TA), gastrocnemius (GA) and quadriceps (QUAD)). Subcutaneous adipose mass in the inguinal fat depot (B, n = 9–12), serum GDF15 (C, n = 8–11) and spleen mass (D, n = 21–22) were also analyzed. mRNA content of inflammatory and atrophy markers interleukin-6 (IL-6), tumour necrosis factor – alpha (TNF-α), atrogin and muscle RING-finger protein-1 (MURF-1) were measured using quantitative PCR in the TA and diaphragm of all groups (E-H, n = 6–8). Results represent mean ± SD. Lettering denotes statistical significance when different from each other ( p < 0.05). C57BL/6J female mice ∼75 days post PBS injection as controls (CTRL); C57BL/6J female mice ∼45 days post ovarian cancer injection (45 Days); C57BL/6J female mice ∼75 days post ovarian cancer injection (75 Days); C57BL/6J female mice ∼90 days post ovarian cancer injection (90 Days). All data was analyzed using a one-way ANOVA or Kruskal–Wallis test when data did not fit normality. All ANOVAs were followed by a two-stage step-up method of Benjamini, Krieger and Yukutieli multiple comparisons test.

    Techniques Used: Expressing, Muscles, Real-time Polymerase Chain Reaction, Injection



    Similar Products

    gdf15 growth differentiation factor 15 levels  (R&D Systems)
    94
    R&D Systems gdf15 growth differentiation factor 15 levels
    The effects of ID8 implantation on muscle mass, fat mass, spleen mass, <t>GDF15</t> and gene expression of inflammation and atrogenes. Analysis of muscle mass at all time points in hindlimb muscles was completed (A, n = 22–24; soleus (SOL), extensor digitorum longus (EDL), plantaris (PLA), tibialis anterior (TA), gastrocnemius (GA) and quadriceps (QUAD)). Subcutaneous adipose mass in the inguinal fat depot (B, n = 9–12), serum GDF15 (C, n = 8–11) and spleen mass (D, n = 21–22) were also analyzed. mRNA content of inflammatory and atrophy markers interleukin-6 (IL-6), tumour necrosis factor – alpha (TNF-α), atrogin and muscle RING-finger protein-1 (MURF-1) were measured using quantitative PCR in the TA and diaphragm of all groups (E-H, n = 6–8). Results represent mean ± SD. Lettering denotes statistical significance when different from each other ( p < 0.05). C57BL/6J female mice ∼75 days post PBS injection as controls (CTRL); C57BL/6J female mice ∼45 days post ovarian cancer injection (45 Days); C57BL/6J female mice ∼75 days post ovarian cancer injection (75 Days); C57BL/6J female mice ∼90 days post ovarian cancer injection (90 Days). All data was analyzed using a one-way ANOVA or Kruskal–Wallis test when data did not fit normality. All ANOVAs were followed by a two-stage step-up method of Benjamini, Krieger and Yukutieli multiple comparisons test.
    Gdf15 Growth Differentiation Factor 15 Levels, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gdf15 growth differentiation factor 15 levels/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    gdf15 growth differentiation factor 15 levels - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    The effects of ID8 implantation on muscle mass, fat mass, spleen mass, GDF15 and gene expression of inflammation and atrogenes. Analysis of muscle mass at all time points in hindlimb muscles was completed (A, n = 22–24; soleus (SOL), extensor digitorum longus (EDL), plantaris (PLA), tibialis anterior (TA), gastrocnemius (GA) and quadriceps (QUAD)). Subcutaneous adipose mass in the inguinal fat depot (B, n = 9–12), serum GDF15 (C, n = 8–11) and spleen mass (D, n = 21–22) were also analyzed. mRNA content of inflammatory and atrophy markers interleukin-6 (IL-6), tumour necrosis factor – alpha (TNF-α), atrogin and muscle RING-finger protein-1 (MURF-1) were measured using quantitative PCR in the TA and diaphragm of all groups (E-H, n = 6–8). Results represent mean ± SD. Lettering denotes statistical significance when different from each other ( p < 0.05). C57BL/6J female mice ∼75 days post PBS injection as controls (CTRL); C57BL/6J female mice ∼45 days post ovarian cancer injection (45 Days); C57BL/6J female mice ∼75 days post ovarian cancer injection (75 Days); C57BL/6J female mice ∼90 days post ovarian cancer injection (90 Days). All data was analyzed using a one-way ANOVA or Kruskal–Wallis test when data did not fit normality. All ANOVAs were followed by a two-stage step-up method of Benjamini, Krieger and Yukutieli multiple comparisons test.

    Journal: Molecular Metabolism

    Article Title: Muscle weakness and mitochondrial stress occur before severe metastasis in a novel mouse model of ovarian cancer cachexia

    doi: 10.1016/j.molmet.2024.101976

    Figure Lengend Snippet: The effects of ID8 implantation on muscle mass, fat mass, spleen mass, GDF15 and gene expression of inflammation and atrogenes. Analysis of muscle mass at all time points in hindlimb muscles was completed (A, n = 22–24; soleus (SOL), extensor digitorum longus (EDL), plantaris (PLA), tibialis anterior (TA), gastrocnemius (GA) and quadriceps (QUAD)). Subcutaneous adipose mass in the inguinal fat depot (B, n = 9–12), serum GDF15 (C, n = 8–11) and spleen mass (D, n = 21–22) were also analyzed. mRNA content of inflammatory and atrophy markers interleukin-6 (IL-6), tumour necrosis factor – alpha (TNF-α), atrogin and muscle RING-finger protein-1 (MURF-1) were measured using quantitative PCR in the TA and diaphragm of all groups (E-H, n = 6–8). Results represent mean ± SD. Lettering denotes statistical significance when different from each other ( p < 0.05). C57BL/6J female mice ∼75 days post PBS injection as controls (CTRL); C57BL/6J female mice ∼45 days post ovarian cancer injection (45 Days); C57BL/6J female mice ∼75 days post ovarian cancer injection (75 Days); C57BL/6J female mice ∼90 days post ovarian cancer injection (90 Days). All data was analyzed using a one-way ANOVA or Kruskal–Wallis test when data did not fit normality. All ANOVAs were followed by a two-stage step-up method of Benjamini, Krieger and Yukutieli multiple comparisons test.

    Article Snippet: GDF15 (Growth differentiation factor 15) levels were analyzed in serum using the mouse GDF-15 DuoSet ELISA kit according to the manufacturer's instructions (R&D Systems DY6385).

    Techniques: Expressing, Muscles, Real-time Polymerase Chain Reaction, Injection